MindWalk’s Preclinical Dengue Data Support a HYFT® Computational Prediction: Immunogens Designed on the Predicted Target Elicited Cross-Reactive Antibodies Against Antigens of All Four Dengue Serotypes, Reproduced Across Two Independent Campaigns

MindWalk’s preclinical results show promising potential for a new dengue vaccine, using its HYFT® technology to computationally identify a target that could induce antibodies effective against all four dengue virus types. This breakthrough suggests a single vaccine could protect against the entire spectrum of dengue viruses, which is crucial given the complexity and global impact of the disease. These findings could significantly advance dengue prevention strategies, offering a more effective and comprehensive solution compared to current single-serotype vaccines.